ESPR
Esperion Therapeutics, Inc.
$3.15
+0.64%
$808.3M
No data for this timeframe.
Vol
Market Cap$808.3M
Cap SizeSmall Cap
Analyst ConsensusSell (0%)
Inst. Holders8 funds
Inst. Value$100.5M
Inst. Activity5 buys / 0 sells
Insider Activity0B / 3S
Insider Net $-$102.4K
Reddit Sentiment33° Cool
SEC Reports7
Press Releases4
Recent Activity
Jun 9, 2026
SEC
Esperion Therapeutics disclosed that the German Federal Cartel Office (Bundeskartellamt) cleared the pending acquisition
8-K — Impact 6/10
Jun 8, 2026
SEC
The filing is a definitive merger proxy (DEFM14A) for Esperion Therapeutics' acquisition by ArchiMed for $3.16/share plu
DEFM14A — Impact 7/10
Jun 5, 2026
SEC
Esperion Therapeutics filed an 8-K reporting the results of its 2026 annual meeting of stockholders held on May 28, 2026
8-K — Impact 3/10
May 28, 2026
Insider
Shepard Jay sold 79,873 shares
Director @ $0.00 ($0.00)
May 28, 2026
Insider
CARROLL J MARTIN sold 79,873 shares
Director @ $0.00 ($0.00)
May 28, 2026
Insider
THOMPSON JOHN CRAIG sold 79,873 shares
Director @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
4,742,082 shares ($17.5M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
2,194,600 shares ($8.1M)
Price Targets
$3.19
+1.6% upside
Hold
Current $3.14
Low $3.16
Median $3.16
High $3.28
4 analysts
$3.16
$3.28
Analyst Ratings
0Strong Buy
0Buy
8Hold
1Sell
2Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 4, 2026 | Needham | DOWNGRADE | Buy → Hold |
| May 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Mar 13, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Mar 3, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.07 ▼ -949.5% | $-0.07 — $-0.07 | -250% YoY | 1 |
| Next Q | $-0.04 ▼ -699.7% | $-0.04 — $-0.04 | 75% YoY | 1 |
| Current FY | $-0.21 ▼ -1675.4% | $-0.21 — $-0.21 | -91% YoY | 1 |
| Next FY | $0.29 | $0.09 — $0.43 | 239% YoY | 5 |
Latest Reports
BULLISH
8-K
6/10
Esperion Therapeutics disclosed that the German Federal Cartel Office (Bundeskartellamt) cleared the pending acquisition
Jun 9, 2026
BULLISH
DEFM14A
7/10
The filing is a definitive merger proxy (DEFM14A) for Esperion Therapeutics' acquisition by ArchiMed for $3.16/share plu
Jun 8, 2026
NEUTRAL
Press
5/10
Esperion presented Phase 2 pediatric data and a CLEAR Outcomes post-hoc analysis at EAS 2026, showing bempedoic acid red
May 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $55.3M | — |
| TWO SIGMA INVESTMENTS, LP | $17.5M | DOUBLED |
| MORGAN STANLEY | $13.0M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $8.1M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $2.6M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 28, 2026 | Shepard Jay | A | $0.00 |
| May 28, 2026 | CARROLL J | A | $0.00 |
| May 28, 2026 | THOMPSON JOHN | A | $0.00 |
| May 28, 2026 | Hoffman Robert | A | $0.00 |
| May 28, 2026 | Fischer Seth | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
8 institutional holders with $100.5M total value (27,152,065 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, MORGAN. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 14,945,454 | $55.3M | 55.0% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 4,742,082 | $17.5M | 17.5% | DOUBLED +111.8% |
| 3 | MORGAN STANLEY | 3,514,227 | $13.0M | 12.9% | DOUBLED +284.2% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 2,194,600 | $8.1M | 8.1% | DOUBLED +183.6% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 715,326 | $2.6M | 2.6% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 696,790 | $2.6M | 2.6% | DOUBLED +128.8% |
| 7 | WELLS FARGO & COMPANY/MN | 263,188 | $973.8K | 1.0% | ADD +80.4% |
| 8 | FMR LLC | 80,398 | $297.5K | 0.3% | ADD +27.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 2,238,618 | 4,742,082 | +111.8% | $17.5M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 773,900 | 2,194,600 | +183.6% | $8.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 304,572 | 696,790 | +128.8% | $2.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 145,853 | 263,188 | +80.4% | $973.8K | 2025-Q4 |
| FMR LLC | ADD | 63,323 | 80,398 | +27.0% | $297.5K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 1,055,488 | 4,055,626 | +284.2% | $10.7M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 292,400 | 773,900 | +164.7% | $2.1M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 836,339 | 304,572 | -63.6% | $807.1K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 2,731,287 | 1,827,994 | -33.1% | $1.8M | 2025-Q2 |
| UBS Group AG | DOUBLED | 669,918 | 1,537,212 | +129.5% | $1.5M | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 6,586,632 | 1,055,488 | -84.0% | $1.0M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,527,263 | 836,339 | -45.2% | $823.0K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 292,400 | — | $287.8K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 1,217,541 | 123,448 | -89.9% | $121.5K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 108,401 | 1,217,541 | +1023.2% | $1.8M | 2025-Q1 |
| FMR LLC | TRIM | 111,261 | 73,170 | -34.2% | $105.4K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 578,800 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 2,646,199 | 6,309,377 | +138.4% | $13.9M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 575,716 | 2,408,632 | +318.4% | $5.3M | 2024-Q4 |
| UBS Group AG | DOUBLED | 90,293 | 876,942 | +871.2% | $1.9M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 914,100 | 578,800 | -36.7% | $1.3M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 554,914 | — | $915.6K | 2024-Q3 |
8 unique insiders with 3 transactions. Net insider value: -$102.4K ($0.00 bought, $102.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 28, 2026 | Shepard Jay | Director | A | 79,873 | $0.00 | $0.00 |
| May 28, 2026 | CARROLL J MARTIN | Director | A | 79,873 | $0.00 | $0.00 |
| May 28, 2026 | THOMPSON JOHN CRAIG | Director | A | 79,873 | $0.00 | $0.00 |
| May 28, 2026 | Hoffman Robert E. | Director | A | 79,873 | $0.00 | $0.00 |
| May 28, 2026 | Fischer Seth H. Z. | Director | A | 79,873 | $0.00 | $0.00 |
| Mar 17, 2026 | Looker Benjamin | Chief Legal Officer | SELL | 5,708 | $2.70 | $15.4K |
| Mar 17, 2026 | Halladay Benjamin | Chief Financial Officer | SELL | 6,424 | $2.71 | $17.4K |
| Mar 17, 2026 | Koenig Sheldon L. | President and CEO | SELL | 25,578 | $2.72 | $69.5K |
| Mar 13, 2026 | Halladay Benjamin | Chief Financial Officer | A | 247,430 | $0.00 | $0.00 |
| Mar 13, 2026 | Koenig Sheldon L. | President and CEO | A | 723,760 | $0.00 | $0.00 |
| Mar 13, 2026 | Looker Benjamin | Chief Legal Officer | A | 300,840 | $0.00 | $0.00 |
| Mar 13, 2026 | Koenig Sheldon L. | President and CEO | A | 647,460 | $0.00 | $0.00 |
| Mar 13, 2026 | Halladay Benjamin | Chief Financial Officer | A | 221,270 | $0.00 | $0.00 |
| Mar 13, 2026 | Looker Benjamin | Chief Legal Officer | A | 269,230 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 5.1/10.
BULLISH
8-K
6/10
Esperion Therapeutics disclosed that the German Federal Cartel Office (Bundeskartellamt) cleared the
Jun 9, 2026
BULLISH
DEFM14A
7/10
The filing is a definitive merger proxy (DEFM14A) for Esperion Therapeutics' acquisition by ArchiMed
Jun 8, 2026
NEUTRAL
8-K
3/10
Esperion Therapeutics filed an 8-K reporting the results of its 2026 annual meeting of stockholders
Jun 5, 2026
BULLISH
PREM14A
6/10
Esperion Therapeutics has filed a preliminary proxy statement (PREM14A) for its acquisition by an af
May 29, 2026
BULLISH
DEFA14A
7/10
Esperion Therapeutics entered into a definitive agreement to be acquired by ARCHIMED for $3.16 per s
May 1, 2026
NEUTRAL
PRESS-RELEASE
3/10
Esperion Therapeutics announced it will report first quarter 2026 financial results on May 7, 2026.
Apr 23, 2026
NEUTRAL
CLUSTER
4/10
Multiple executives at Esperion Therapeutics, including the CEO, CFO, and Chief Legal Officer, sold
Mar 18, 2026
NEUTRAL
5/10
Esperion presented Phase 2 pediatric data and a CLEAR Outcomes post-hoc analysis at EAS 2026, showin
May 26, 2026
BULLISH
7/10
Esperion has agreed to be acquired by ARCHIMED for $3.16 per share in cash at closing, plus continge
May 1, 2026
BULLISH
8/10
Esperion Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenu
Mar 10, 2026
BULLISH
8/10
Esperion Therapeutics is acquiring Corstatis Therapeutics to gain full rights to Enbumyst™, the firs
Mar 3, 2026
Current analyst consensus: Strong Sell (0% buy). Based on 11 analysts: 0 strong buy, 0 buy, 8 hold, 1 sell, 2 strong sell.
Analyst Price Targets
$3.19 mean target
+1.6% upside
Hold (3.00)
$3.16 Low
$3.28 High
| Metric | Value |
|---|---|
| Current Price | $3.14 |
| Target Low | $3.16 |
| Target Mean | $3.19 |
| Target Median | $3.16 |
| Target High | $3.28 |
| # Analysts | 4 |
| Recommendation | Hold (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.07 | $-0.07 | $-0.07 | -250.0% | -949.5% | 1↑ 0↓ | $0.1B | -7.0% | 1 |
| Next Q 2026-09-30 |
$-0.04 | $-0.04 | $-0.04 | 75.0% | -699.7% | 1↑ 0↓ | $0.1B | -2.1% | 1 |
| Current FY 2026-12-31 |
$-0.21 | $-0.21 | $-0.21 | -90.9% | -1675.4% | 1↑ 0↓ | $0.3B | -16.3% | 1 |
| Next FY 2027-12-31 |
$0.29 | $0.09 | $0.43 | 239.0% | -0.5% | — | $0.5B | 35.3% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.070 | |
| 7d ago | $0.000 | -0.070 |
| 30d ago | $-0.007 | -0.063 |
| 60d ago | $-0.007 | -0.063 |
| 90d ago | $0.013 | -0.083 |
3 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 4, 2026 | Needham | DOWNGRADE | Buy | Hold |
| May 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Mar 13, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 3, 2026 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 8 | 1 | 2 | 0% | |
| May 1, 2026 | 3 | 8 | 2 | 1 | 0 | 79% | |
| Apr 1, 2026 | 3 | 8 | 2 | 1 | 0 | 79% | |
| Mar 1, 2026 | 3 | 8 | 2 | 1 | 0 | 79% | |
| Feb 1, 2026 | 3 | 8 | 2 | 1 | 0 | 79% | |
| Jan 1, 2026 | 3 | 8 | 2 | 1 | 0 | 79% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
May 26, 2026
fda
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
<p align="center"><em>– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years –</em></p>
May 14, 2026
other
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
<p>ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employ
May 13, 2026
short_interest
FTD: ESPR — 180,408 shares ($0.6M) failed to deliver
Settlement: 20260513, Price: $3.13, FTD Value: $564,677.04, ESPERION THERAPEUTICS INC NEW
May 7, 2026
earnings_calendar
ESPR Q1 2026 Earnings Scheduled — 2026-05-07
May 7, 2026
short_interest
FTD: ESPR — 244,391 shares ($0.8M) failed to deliver
Settlement: 20260507, Price: $3.15, FTD Value: $769,831.65, ESPERION THERAPEUTICS INC NEW
May 6, 2026
short_interest
FTD: ESPR — 234,738 shares ($0.7M) failed to deliver
Settlement: 20260506, Price: $3.12, FTD Value: $732,382.56, ESPERION THERAPEUTICS INC NEW
May 5, 2026
short_interest
FTD: ESPR — 351,980 shares ($1.1M) failed to deliver
Settlement: 20260505, Price: $3.12, FTD Value: $1,098,177.6, ESPERION THERAPEUTICS INC NEW
May 4, 2026
short_interest
FTD: ESPR — 2,144,413 shares ($6.7M) failed to deliver
Settlement: 20260504, Price: $3.11, FTD Value: $6,669,124.43, ESPERION THERAPEUTICS INC NEW
May 1, 2026
m_and_a
Esperion to be Acquired by ARCHIMED
<p align="center"><em>Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggr
May 1, 2026
short_interest
FTD: ESPR — 563,578 shares ($1.1M) failed to deliver
Settlement: 20260501, Price: $2.00, FTD Value: $1,127,156, ESPERION THERAPEUTICS INC NEW
Apr 27, 2026
short_volume
Short Volume: ESPR — 58.9% short (2.0M / 3.5M)
Short: 2,048,889 | Exempt: 27,666 | TRF Vol: 3,478,961 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: ESPR — 62.4% short (2.4M / 3.9M)
Short: 2,429,426 | Exempt: 17,525 | TRF Vol: 3,890,864 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
earnings
Esperion to Report First Quarter 2026 Financial Results on May 7
<p>ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results
Apr 23, 2026
short_volume
Short Volume: ESPR — 61.3% short (1.1M / 1.8M)
Short: 1,089,307 | Exempt: 9,728 | TRF Vol: 1,777,452 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: ESPR — 70.5% short (3.3M / 4.7M)
Short: 3,322,416 | Exempt: 20,658 | TRF Vol: 4,713,603 | Short Ratio: 70.5% | Off-exchange volume (dark pool + OTC)